CHARLOTTESVILLE, Virginia, February8, 2011 — Biovista announced today that it is co-presenting a webinar with FDA/OCP on Predicting Serious Adverse Events Using Mechanism of Action, on Thursday, 24 February 2011. Biovista’s President, Dr. Aris Persidis, will co-present together with Dr. Darrell Abernathy, Associate Director for Drug Safety in the Office of Clinical Pharmacology at the … Read More
Author: Vassilis Virvilis
Biovista Inc. to Present at 4th Annual OneMedForum and Biotech Showcase™ in San Francisco
Charlottesville, VA – January 4, 2011 – Biovista Inc., a privately held drug discovery company focused on finding novel uses for existing drugs, announced today that Aris Persidis, Ph.D, president and co-founder of Biovista, will be presenting at the 4th Annual OneMedForum 2011 conference. Dr. Persidis’ presentation will be given at the Sir Francis Drake … Read More
Bioworld: Biovista AI boosts Drug Discovery
BioVista’s Artificial Intelligence Platform Boosts Drug Discovery BioVista has eight ongoing projects that involve using its technology to provide discovery, repositioning, adverse event profiling, patient stratification and other services for partners…BioVista said partnering discussions are ongoing for BVA-201 and BVA-601, but the company has not yet determined how far into preclinical and possibly clinical studies … Read More
BioWorld: A Deep Dive into Pfizer’s Emerging Biotech Strategy
By Arlene Weintraub, BioWorld Insight On Nov. 9, the company formed a research collaboration with Biovista Inc…
Biovista Announces a Drug Repositioning Collaboration With Pfizer
CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ — Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of the collaboration is to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista’s Clinical Outcome Search Space (COSS) technology. Under the terms … Read More